Hypermethylation in SFRP2 promoter in  human leukemia K562 cells and bone marrow specimen with chronic myeloid leukemia

Song Junjun; Li Ying; Yang Zesong; Yang Li; Chen Jianbin

您当前的位置：

首页 >

文章列表页 >

Hypermethylation in SFRP2 promoter in human leukemia K562 cells and bone marrow specimen with chronic myeloid leukemia

更新时间：2025-01-15

- Hypermethylation in SFRP2 promoter in human leukemia K562 cells and bone marrow specimen with chronic myeloid leukemia
- Journal of Army Medical University Vol. 33, Issue 24, Pages: 2583-2586(2011)
- 作者机构：
  
  1. 重庆医科大学附属第一医院：血液科，血液科实验室
  2. 重庆医科大学卫生统计学教研室
- 作者简介：
- 基金信息：
- DOI：
  CLC： R363.21;R394.3;R733.72
- Published：2011，
  
  Published Online：30 December 2011，
- 稿件说明：
移动端阅览
SONG JUNJUN, LI YING, YANG ZESONG, et al. Hypermethylation in SFRP2 promoter in human leukemia K562 cells and bone marrow specimen with chronic myeloid leukemia. [J]. Journal of army medical university, 2011, 33(24): 2583-2586.
DOI：

SONG JUNJUN, LI YING, YANG ZESONG, et al. Hypermethylation in SFRP2 promoter in human leukemia K562 cells and bone marrow specimen with chronic myeloid leukemia. [J]. Journal of army medical university, 2011, 33(24): 2583-2586. DOI：

摘要

目的研究慢性粒细胞白血病（chronic myeloid leukemia，CML）骨髓细胞SFRP2基因启动子甲基化状态，探讨SFRP2基因启动子甲基化在CML发病机制中的作用。方法分别采用RT-PCR、甲基化特异性PCR（methylation-specific PCR

MSP）方法检测CML细胞系K562细胞及骨髓标本SFRP2 mRNA及 SFRP2基因启动子CpG岛甲基化状态；并予DNA甲基化转移酶抑制剂5-氮杂-2’-脱氧胞苷（Aza）联合组蛋白去乙酰化酶抑制剂曲古菌素A（TSA）处理K562细胞，观察其SFRP2 mRNA表达情况。结果 SFRP2 mRNA在K562细胞、CML和正常人骨髓标本表达率分别为0、22%（4/18）、100%（8/8）（

0.05）；SFRP2基因启动子甲基化率在K562细胞、CML和正常人骨髓标本分别为100%、66%（25/38）、0（0/13）（

0.05）；伴随K562细胞去甲基化药物处理后未甲基化序列的增加，其SFRP2 mRNA恢复了表达。结论 CML骨髓细胞的SFRP2基因启动子存在高甲基化现象，SFRP2基因启动子甲基化可能是CML发生发展的分子机制之一，提示了其甲基化可能成为CML的新的参考标记物。

Abstract

Objective To determine the methylation status of secreted frizzled-related protein 2 (SFRP2) gene in chronic myeloid leukemia (CML) bone marrow cells

and try to find the role of its promoter methylation during the tumorigenesis of CML. Methods The expression of SFRP2 in CML cell line K562

bone marrow specimens of identified CML patients and health volunteers were detected with semi-quantitative PCR (RT-PCR).

The methylation status of SFRP2 promoter was detected in K562 cells and CML bone marrow specimens by methylation-specific PCR (MSP). After K562 cells was treated with pharmacological demethylation 5-aza-2’deoxycytidine (Aza) and trichostatin A(TSA)

the expression of SFRP2 was detected again with RT-PCR. Results SFRP2 was silenced in K562 cells

expressed in 22.0% (4/18) CML bone marrow specimens

and detected in all normal bone marrow samples (100.0%

8/8

0.05). The frequencies of SFRP2 promoter methylation were 100%

66% (25/38) and 0 (0/13) respectively in K562 cells

CML bone marrow and normal bone marrow specimens (

0.05). Pharmacological demethylation treatment dramatically induced mRNA expression of SFPR2

and this reactivation was associated with an increase of unmethylation alleles. Conclusion The promoter of SFRP2 gene are hypermethylated in CML

which be one of the molecular mechanisms of CML. Its hypermethylation might serve as a new biomarker for CML.

关键词

慢性粒细胞白血病SFRP2甲基化去甲基化

Keywords

chronic myeloid leukemiasecreted frizzled-related protein 2methylationdemethylation

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Role of estrogen receptor α in process of insulin-induced atherosclerosis

Effects of Polygonum multiflorum extract on DNA methylation and gene transcription in brain tissue of aging mice

Clinical significance of BCL2L10 expression and promoter methylation in myelodysplastic syndrome

Related Author

WANG Junlan

CHEN Yupeng

ZHANG Sheng

CHEN Linying

HUANG Qian

ZHANG Zhenzhen

ZHOU Sijie

LIU Sihao

Related Institution

Department of Pathology, the First Affiliated Hospital of Fujian Medical University

Institue of Life Sciences, Chongqing Medical University

Department of Medical Genetics, College of Basic Medical Sciences, Third Military Medical University

Department of Cardiology, Institute of Surgery Research, Daping Hospital, Third Military Medical University

Department of Molecular Biology and Biochemistry, Zunyi Medical University

⁰